Sanjiv S. Agarwala, MD

Professor
Temple University School of Medicine
Philadelphia, PA

Authored Items

Benefits of Dual I-O Therapy in Metastatic Uveal Melanoma
By Sanjiv S. Agarwala, MD
Dual IO 2021 - Year in Review
Dual IO 2021 - Year in Review
The combination of nivolumab and ipilimumab offers deep and sustained responses and improved overall survival in malignant uveal melanoma. Read More ›
Dual Immune Checkpoint Inhibitors in Advanced Cutaneous Melanoma
By Sanjiv S. Agarwala, MD
Dual IO 2021 - Year in Review
Dual IO 2021 - Year in Review
Dual immunotherapy provides significant and durable benefits as first-line treatment and as neoadjuvant therapy in advanced melanoma. Read More ›
Conference Correspondent Coverage is Brought to You by the Publishers of:
American Health & Drug Benefits
CONQUER: the patient voice
Journal of Hematology Oncology Pharmacy
Journal of Oncology Navigation & Survivorship
Oncology Practice Management
Personalized Medicine in Oncology
The Oncology Nurse–APN/PA
The Oncology Pharmacist
Value-Based Cancer Care

Learn more about our family of publications.

View Our Publications

© Amplity Health. All Rights Reserved. Privacy Policy